Press Releases Molecular Partners AG

Equities

MOLN

CH0256379097

Delayed Swiss Exchange Other stock markets 08:01:23 29/04/2024 BST			5-day change	1st Jan Change
3.105 ^CHF	-7.59%		-5.91%	-9.74%

03-15	Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
03-15	Molecular Partners Swings to Loss in FY23; Revenue Down	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecular Partners : Annual General Meeting Minutes	04-26	PU
Life Science Cares Launches in Switzerland	04-19	GL
Molecular Partners : statement regarding Passive Foreign Investment Company status	04-18	PU
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	04-17	GL
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting	04-17	AQ
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	04-01	AQ
Molecular Partners Publishes Invitation to Annual General Meeting 2024	03-26	GL
Molecular Partners Publishes Invitation to Annual General Meeting 2024	03-26	AQ
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023	03-14	GL
Molecular Partners Announces Dismissal of Class Action Lawsuit	03-01	GL
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	03-01	GL
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations	03-01	AQ
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference	01-07	AQ
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies	01-05	AQ
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences	12-14	AQ
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting	12-10	AQ
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting	12-10	GL
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)	11-14	AQ
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting	11-03	AQ
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition	11-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Molecular Partners AG

Equities

MOLN

CH0256379097

Press Releases

Filters